Israel biotech seeks investment
This article was originally published in Clinica
If $3-4 billion of public and private funds were invested in the Israeli biotechnology sector, sales would be boosted to somewhere in the region of $4 billion within 5-7 years. This is the view put forward by Professor Haim Aviv at a meeting of the board of governors of the Israel-US Binationational and Industrial Research Foundation (BIRD). He said that currently Israel's 160 biotech companies make aggregate sales in the region of $800 million, but that the sector had enjoyed phenomenal growth over the past decade. Further growth was, however, being hampered by lack of financial resources and managerial skill, Professor Aviv said.